AstraZeneca: Sonesitatug Vedotin Reduced the Risk of Death by 42% in 2nd and Later-line CLDN18.2-positive Advanced Gastric/GEJ Cancers in CLARITY-Gastric01
October 27, 2026
October 27, 2026
WILMINGTON, Delaware, Oct. 27 -- AstraZeneca, a biopharmaceutical company, issued the following news release:
* * *
Sonesitatug vedotin reduced the risk of death by 42% in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers in CLARITY-Gastric01
25 October 2026
Sone-Ve reduced the risk of death by 53% in 3rd and later-line setting in primary endpoint
Consistent data across CLDN18.2 expression levels supports potential . . .
* * *
Sonesitatug vedotin reduced the risk of death by 42% in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers in CLARITY-Gastric01
25 October 2026
Sone-Ve reduced the risk of death by 53% in 3rd and later-line setting in primary endpoint
Consistent data across CLDN18.2 expression levels supports potential . . .